Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.77 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.61 |
| ▸ | ACP1 | P24666 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534366 | 1.00 | AKR1B1 (0.77) | AKR1B1ADAMTS5PTPN1ENPP2PTPN2 | |
| SCHEMBL5218036 | 0.91 | AKR1B1 (0.89) | AKR1B1ADAMTS5PTPN1ENPP2 | |
| SCHEMBL5218032 | 0.91 | AKR1B1 (0.89) | AKR1B1ADAMTS5PTPN1ENPP2 | |
| SCHEMBL20534413 | 0.83 | AKR1B1 (1.00) | AKR1B1PTPN1ENPP2PTPN2ACP1 | |
| SCHEMBL20534415 | 0.83 | AKR1B1 (1.00) | AKR1B1PTPN1ENPP2PTPN2ACP1 | |
| SCHEMBL186520 | 0.81 | ADAMTS5 (1.00) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL245003 | 0.81 | ADAMTS5 (1.00) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL5217054 | 0.80 | ADAMTS5 (0.89) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL5217062 | 0.80 | ADAMTS5 (0.89) | AKR1B1ADAMTS5PTPN1 | |
| SCHEMBL20534282 | 0.80 | CA9 (0.71) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
| EP-3609494-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | La Trobe University (AU) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018187845-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | AKR1B1 225/4885ADAMTS5 3027/4885PTPN1 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.